



Endologix  
Investor Relations Department  
2 Musick  
Irvine, CA 92618  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: ELGX

Last Trade:	4.29
Trade Time:	4:00 PM ET Sep 20, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	4.08 - 13.30
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

- Addressing a signi... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Sep 11, 2017*

[Endologix Announces Collaboration Agreements with Japan Lifeline for the Development and Commercialization of Thoracic Endovascular Systems in Japan](#)

*Aug 17, 2017*

[Endologix Announces Positive Clinical Results from the LEOPARD Clinical Study](#)

*Aug 2, 2017*

[Endologix Reports Second Quarter 2017 Financial Results](#)

*Jul 12, 2017*

[Endologix, Inc. to Announce Second Quarter 2017 Financial Results on August 2, 2017](#)

*Jul 10, 2017*

[Endologix, Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference](#)

## Financials [\[ View all \]](#)

[Second Quarter Financial Results](#)

*Mar 1, 2017*

[Annual Report \(10-K\)](#)

*May 1, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Aug 4, 2017*

[Quarterly Report \(10-Q\)](#)

*May 5, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 8, 2016*

[Quarterly Report \(10-Q\)](#)